Critical Review: Mitesco (OTCMKTS:MITI) versus Schrodinger (NASDAQ:SDGR)

Mitesco (OTCMKTS:MITI) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Profitability

This table compares Mitesco and Schrodinger’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mitesco	-7,638.20%	N/A	-2,270.77%
Schrodinger	-40.37%	-29.47%	-14.69%

Institutional and Insider Ownership

0.0% of Mitesco shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 4.9% of Mitesco shares are owned by company insiders. Comparatively, 21.0% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Mitesco and Schrodinger, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mitesco	0	0	0	0	0.00
Schrodinger	1	4	4	0	2.33

Schrodinger has a consensus price target of $20.50, suggesting a potential upside of 65.32%. Given Schrodinger’s stronger consensus rating and higher probable upside, analysts plainly believe Schrodinger is more favorable than Mitesco.

Valuation and Earnings

This table compares Mitesco and Schrodinger”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mitesco	$40,000.00	63.25	-$2.51 million	($0.14)	-0.89
Schrodinger	$255.87 million	3.58	-$103.26 million	($1.42)	-8.73

Mitesco has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Mitesco, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Mitesco has a beta of 5.6, meaning that its stock price is 460% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Summary

Schrodinger beats Mitesco on 8 of the 14 factors compared between the two stocks.

About Mitesco

Mitesco, Inc. does not have significant operations. Previously, it was engaged in healthcare technology and services business. Mitesco, Inc. is based in Vero Beach, Florida.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.